Trial Profile

A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Relacorilant (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Registrational; Therapeutic Use
Acronyms ROSELLA
Sponsors Corcept Therapeutics

22 Jan 2026 Primary endpoint (Overall Survival) has been met.
19 Oct 2025 According to a Corcept Therapeutics media release, Domenica LoRusso is Principal Investigator in the ROSELLA trial.
19 Oct 2025 According to a Corcept Therapeutics media release, results were presented at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com